Skip to content
Research Fellows Directory

Karen Cohen

Dr Karen Cohen

Research Fellow

Organisation

University of Liverpool

Research summary

South Africa has a huge burden of tuberculosis, with an incidence of 1000/100,000 in 2012. Drug induced liver injury occurs in 5% or more of patients taking first-line anti-tuberculosis treatment and is the most common adverse event resulting in ATT interruption. Most patients with drug-induced liver injury due to first-line anti-tuberculosis treatment are rechallenged after clinical and biochemical resolution, as first-line drugs are key to anti-tuberculosis treatment success. Drug-induced liver injury recurs in 11% of rechallenges. Our group recently found that drug-induced liver injury due to first-line anti-tuberculosis treatment is the second most common cause of adverse drug reaction-related death in South African medical wards (Mouton et al 2015).

This project, which is a collaboration between the University of Cape Town and the University of Liverpool, will characterise signature patterns of mechanistic biomarkers that (i) identify drug-induced liver injury due to first-line anti-tuberculosis treatment (ii) detect drug-induced liver injury due to first-line anti-tuberculosis treatment earlier than currently used tests, and (iii) predict recurrence of drug-induced liver injury due to first-line anti-tuberculosis treatment on rechallenge. In addition, we will identify genetic associations with development of drug-induced liver injury due to first-line anti-tuberculosis treatment by means of a genome wide association study.

Grants awarded

Drug induced liver injury due to anti-tuberculosis treatment: predictive mechanism-based biomarkers and genetic associations.

Scheme: Newton Advanced Fellowship

Dates: Mar 2015 - Mar 2018

Value: £111,000